Antibody against tumor specific antigen as target
    3.
    发明授权
    Antibody against tumor specific antigen as target 失效
    针对肿瘤特异性抗原的抗体作为靶标

    公开(公告)号:US07361340B2

    公开(公告)日:2008-04-22

    申请号:US11223812

    申请日:2005-09-09

    Abstract: The present invention relates to a method of detecting cancer by use of an oncogene, a method of screening for an active compound useful to treat and/or prevent cancer, and a pharmaceutical composition for treatment and/or prevention of cancer. More specifically, the present invention provides a method of detecting cancer based on the expression of the human oculospanin gene as a marker and a pharmaceutical composition containing an antibody capable of specifically recognizing human oculospanin and having cytotoxic activity against cancer cells.

    Abstract translation: 本发明涉及通过使用癌基因检测癌症的方法,筛选用于治疗和/或预防癌症的活性化合物的方法和用于治疗和/或预防癌症的药物组合物。 更具体地,本发明提供了一种基于人oculospanin基因作为标记物的表达和含有能够特异性识别人oculospanin并对癌细胞具有细胞毒性活性的抗体的药物组合物来检测癌症的方法。

    SHAPE-DATA ACQUISITION APPARATUS
    7.
    发明公开

    公开(公告)号:US20230334681A1

    公开(公告)日:2023-10-19

    申请号:US18133001

    申请日:2023-04-11

    CPC classification number: G06T7/514 G02B26/105 G06T7/60 G01B11/2518

    Abstract: A shape-data acquisition apparatus obtains shape data of a work surface and includes an illuminator, a transmissive optical element, and an imager. The illuminator has a luminance distribution of a first cycle to irradiate the work surface. The transmissive optical element faces specular reflected light reflected by the work surface and has a transmittance distribution of a second cycle. The imager receives the specular reflected light to capture the work surface. The cyclic directions of the first cycle and the second cycle folded at a mirror image position on the work surface are parallel to each other. A relation of b=a×f2/f1 is satisfied when a is a distance between the illuminator and the work surface, b is a distance between the work surface and the transmissive optical element, f1 is the first cycle, and f2 is the second cycle.

Patent Agency Ranking